What Is the Yale Cancer Vaccine for Dogs
The Yale cancer vaccine for dogs is an experimental immunotherapy designed to train the immune system to recognize and attack cancer cells in dogs. It is developed by researchers at Yale University and aims to treat multiple tumor types, including osteosarcoma, hemangiosarcoma, and other solid tumors in companion animals. The approach uses personalized tumor tissue to create a vaccine that targets neoantigens unique to each dog's cancer, a method similar to modern human cancer vaccine strategies.
Clinical trials have been conducted through Yale's veterinary oncology programs, with data published in peer-reviewed journals and presented at veterinary conferences. The vaccine is not yet commercially approved and remains available primarily through clinical trial participation at select veterinary hospitals and research centers in the United States.
How the Yale Canine Cancer Vaccine Works
Vaccine Mechanism and Targeting
The vaccine is created from a dog's own tumor tissue, which is processed to identify specific mutated proteins. These neoantigens are then used to stimulate the dog's immune system to produce T cells that can recognize and destroy cancer cells. The goal is to reduce tumor burden, delay recurrence, and extend survival times in dogs with various cancers.
Administration and Treatment Schedule
Treatment typically involves a series of vaccine doses administered over several weeks or months, often alongside standard care such as surgery or chemotherapy. Dosing schedules vary by trial protocol, and researchers monitor immune response and tumor markers to evaluate effectiveness.
Current Status, Companies, Costs, and Availability
Trials, Companies, and Research Partners
Yale University leads the core research, with collaborations involving veterinary schools, oncology clinics, and biotech partners focused on animal health. Some trials are supported by grants and partnerships with organizations in the comparative oncology space. Information on active trials can be found on clinical trial registries and through veterinary academic centers.
Costs, Eligibility, and How to Enroll
Costs for the vaccine vary depending on the trial and whether treatment is provided at no cost as part of a research protocol. Eligibility typically requires a confirmed cancer diagnosis, measurable disease, and meeting specific health criteria. Dog owners interested in enrollment should consult with veterinary oncologists at participating institutions or review trial listings on official research databases.